Skip to main content
Erschienen in: Die Onkologie 3/2021

11.12.2020 | Zytostatische Therapie | Leitthema

Systemische Therapie des metastasierten Kolonkarzinoms

Strategien in der Kombinations- und Sequenztherapie

verfasst von: Dr. med. Annika Kurreck, Dominik P. Modest, Jobst von Einem, Sebastian Stintzing

Erschienen in: Die Onkologie | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Beim Kolonkarzinom handelt es sich um eines der häufigsten Malignome in Deutschland. Aufgrund des unterschiedlichen biologischen Verhaltens infolge der molekularen Heterogenität der Kolonkarzinome ist die optimale Kombination und Sequenz der in der palliativen Behandlungssituation verfügbaren Systemtherapien Gegenstand der aktuellen wissenschaftlichen Diskussion.

Ziel der Arbeit

Die zur Behandlung des metastasierten Kolonkarzinoms verfügbaren Systemtherapien (Chemotherapie, monoklonale Antikörper, Immuntherapie) werden beschrieben, die optimale Kombination und Sequenz der Substanzen werden erörtert.

Material und Methoden

Relevante Studien und Expertenempfehlungen werden analysiert und aktuell in Rekrutierung befindliche Studien vorgestellt.

Ergebnisse

In der Systemtherapie des metastasierten Kolonkarzinoms stehen unter Berücksichtigung der molekularen Tumorcharakterisierung (KRAS; NRAS; BRAF; Mikrosatelliteninstabilität, MSI) monoklonale Antikörper, Immuncheckpointinhibitoren und klassische Chemotherapeutika zur Verfügung. Durch die Integration zielgerichteter Substanzen in die Behandlung des metastasierten Kolonkarzinoms kann das Überleben der Patienten signifikant verlängert werden.

Schlussfolgerung

Das Überleben von Patienten mit metastasiertem Kolonkarzinom konnte in den vergangenen Jahren kontinuierlich verbessert werden. Die optimale Therapiekombination und -sequenz wird durch die molekularpathologische Tumorcharakterisierung und die in den nachfolgenden Therapielinien zur Verfügung stehenden Behandlungsoptionen bestimmt.
Literatur
1.
Zurück zum Zitat Robert-Koch-Institut (2019) Krebs in Deutschland 2015/2016, S 38–42 Robert-Koch-Institut (2019) Krebs in Deutschland 2015/2016, S 38–42
2.
Zurück zum Zitat Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2019) S3-Leitlinie Kolorektales Karzinom (2.1) Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2019) S3-Leitlinie Kolorektales Karzinom (2.1)
3.
Zurück zum Zitat Venook APN, Lenz HJ, Innocenti F (2014) CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32:5s (suppl; abstr LBA3)CrossRef Venook APN, Lenz HJ, Innocenti F (2014) CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32:5s (suppl; abstr LBA3)CrossRef
4.
Zurück zum Zitat Stintzing S et al (2017) Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE‑3 (AIO KRK-0306) study. Eur J Cancer 79:50–60PubMedCrossRef Stintzing S et al (2017) Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE‑3 (AIO KRK-0306) study. Eur J Cancer 79:50–60PubMedCrossRef
5.
Zurück zum Zitat Stintzing S et al (2016) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 17(10):1426–1434PubMedCrossRef Stintzing S et al (2016) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 17(10):1426–1434PubMedCrossRef
7.
Zurück zum Zitat Douillard JY et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28(31):4697–4705PubMedCrossRef Douillard JY et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28(31):4697–4705PubMedCrossRef
9.
Zurück zum Zitat Rivera F et al (2017) Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Dis 32(8):1179–1190PubMedPubMedCentralCrossRef Rivera F et al (2017) Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Dis 32(8):1179–1190PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Venook A (2016) Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 34:3504CrossRef Venook A (2016) Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 34:3504CrossRef
11.
Zurück zum Zitat Venook AP et al (2017) Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 317(23):2392–2401PubMedPubMedCentralCrossRef Venook AP et al (2017) Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 317(23):2392–2401PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Modest DP et al (2019) FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, phase II VOLFI study (AIO KRK0109). J Clin Oncol 37(35):3401–3411PubMedCrossRef Modest DP et al (2019) FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, phase II VOLFI study (AIO KRK0109). J Clin Oncol 37(35):3401–3411PubMedCrossRef
13.
Zurück zum Zitat Borelli B et al (2018) TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. ESMO Open 3(4):e403PubMedPubMedCentralCrossRef Borelli B et al (2018) TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. ESMO Open 3(4):e403PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Cremolini C et al (2018) Activity and safety of cetuximab plus modified FOLFOXIRI followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a randomized phase 2 clinical trial. JAMA Oncol 4(4):529–536PubMedPubMedCentralCrossRef Cremolini C et al (2018) Activity and safety of cetuximab plus modified FOLFOXIRI followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a randomized phase 2 clinical trial. JAMA Oncol 4(4):529–536PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Heinemann V et al (2016) A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. Eur J Cancer 67:11–20PubMedCrossRef Heinemann V et al (2016) A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. Eur J Cancer 67:11–20PubMedCrossRef
16.
Zurück zum Zitat Sobrero AF et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26(14):2311–2319PubMedCrossRef Sobrero AF et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26(14):2311–2319PubMedCrossRef
17.
Zurück zum Zitat Sobrero AF et al (2012) Final results from study 181: randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC). J Clin Oncol 30:387CrossRef Sobrero AF et al (2012) Final results from study 181: randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC). J Clin Oncol 30:387CrossRef
18.
Zurück zum Zitat Ciardiello F et al (2016) Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Ann Oncol 27(6):1055–1061PubMedCrossRef Ciardiello F et al (2016) Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Ann Oncol 27(6):1055–1061PubMedCrossRef
19.
Zurück zum Zitat Modest DP et al (2015) Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer. J Clin Oncol 33(32):3718–3726PubMedCrossRef Modest DP et al (2015) Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer. J Clin Oncol 33(32):3718–3726PubMedCrossRef
20.
Zurück zum Zitat Hecht JR et al (2015) SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin Colorectal Cancer 14(2):72–80PubMedCrossRef Hecht JR et al (2015) SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin Colorectal Cancer 14(2):72–80PubMedCrossRef
21.
22.
Zurück zum Zitat Stintzing S et al (2009) Behandlung des kolorektalen Karzinoms mit monoklonalen Antikörpern. Dtsch Arztebl 12:526 Stintzing S et al (2009) Behandlung des kolorektalen Karzinoms mit monoklonalen Antikörpern. Dtsch Arztebl 12:526
23.
Zurück zum Zitat Bokemeyer C et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27(5):663–671PubMedCrossRef Bokemeyer C et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27(5):663–671PubMedCrossRef
24.
Zurück zum Zitat Cunningham D et al (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14(11):1077–1085PubMedCrossRef Cunningham D et al (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14(11):1077–1085PubMedCrossRef
25.
Zurück zum Zitat Saltz LB et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013–2019PubMedCrossRef Saltz LB et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013–2019PubMedCrossRef
26.
Zurück zum Zitat Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342PubMedCrossRef Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342PubMedCrossRef
27.
Zurück zum Zitat Modest DP et al (2019) Sequential versus combination therapy of metastatic colorectal cancer using fluoropyrimidines, irinotecan, and bevacizumab: a randomized, controlled study-XELAVIRI (AIO KRK0110). J Clin Oncol 37(1):22–32PubMedCrossRef Modest DP et al (2019) Sequential versus combination therapy of metastatic colorectal cancer using fluoropyrimidines, irinotecan, and bevacizumab: a randomized, controlled study-XELAVIRI (AIO KRK0110). J Clin Oncol 37(1):22–32PubMedCrossRef
28.
Zurück zum Zitat Cremolini C et al (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16(13):1306–1315. https://doi.org/10.1016/S1470-2045(15)00122-9CrossRef Cremolini C et al (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16(13):1306–1315. https://​doi.​org/​10.​1016/​S1470-2045(15)00122-9CrossRef
29.
Zurück zum Zitat Parikh AR et al (2019) MAVERICC, a randomized, biomarker-stratified, phase II study of mFOLFOX6-bevacizumab versus FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer. Clin Cancer Res 25(10):2988–2995PubMedCrossRef Parikh AR et al (2019) MAVERICC, a randomized, biomarker-stratified, phase II study of mFOLFOX6-bevacizumab versus FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer. Clin Cancer Res 25(10):2988–2995PubMedCrossRef
30.
Zurück zum Zitat Tabernero J et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16(5):499–508PubMedCrossRef Tabernero J et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16(5):499–508PubMedCrossRef
31.
Zurück zum Zitat Tabernero J et al (2014) Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 50(2):320–331PubMedCrossRef Tabernero J et al (2014) Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 50(2):320–331PubMedCrossRef
32.
Zurück zum Zitat Innocenti F et al (2019) Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome. J Clin Oncol 37(14):1217–1227PubMedPubMedCentralCrossRef Innocenti F et al (2019) Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome. J Clin Oncol 37(14):1217–1227PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Van Cutsem E et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386–1422PubMedCrossRef Van Cutsem E et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386–1422PubMedCrossRef
34.
Zurück zum Zitat Cremolini C et al (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16(13):1306–1315PubMedCrossRef Cremolini C et al (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16(13):1306–1315PubMedCrossRef
35.
Zurück zum Zitat Loupakis F et al (2014) FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 50(1):57–63PubMedCrossRef Loupakis F et al (2014) FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 50(1):57–63PubMedCrossRef
37.
Zurück zum Zitat Rowland A et al (2015) Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 112(12):1888–1894PubMedPubMedCentralCrossRef Rowland A et al (2015) Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 112(12):1888–1894PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Pietrantonio F et al (2015) Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 51(5):587–594PubMedCrossRef Pietrantonio F et al (2015) Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 51(5):587–594PubMedCrossRef
39.
40.
Zurück zum Zitat Kopetz S et al (2020) Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). J Clin Oncol 38(15_suppl):4001–4001CrossRef Kopetz S et al (2020) Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). J Clin Oncol 38(15_suppl):4001–4001CrossRef
41.
Zurück zum Zitat Kopetz S (2017) Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). J Clin Oncol 35(4_suppl):520–552CrossRef Kopetz S (2017) Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). J Clin Oncol 35(4_suppl):520–552CrossRef
42.
Zurück zum Zitat Corcoran RB et al (2018) Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov 8(4):428–443PubMedPubMedCentralCrossRef Corcoran RB et al (2018) Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov 8(4):428–443PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Grothey A et al (2020) Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC. Ann Oncol 31(3):243CrossRef Grothey A et al (2020) Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC. Ann Oncol 31(3):243CrossRef
44.
Zurück zum Zitat Andre T et al (2020) Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: the phase 3 KEYNOTE-177 study. J Clin Oncol 38(18_suppl):LBA4-LBA4CrossRef Andre T et al (2020) Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: the phase 3 KEYNOTE-177 study. J Clin Oncol 38(18_suppl):LBA4-LBA4CrossRef
45.
Zurück zum Zitat Overman MJ et al (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18(9):1182–1191PubMedPubMedCentralCrossRef Overman MJ et al (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18(9):1182–1191PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Overman MJ et al (2018) Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36(8):773–779PubMedCrossRef Overman MJ et al (2018) Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36(8):773–779PubMedCrossRef
47.
Zurück zum Zitat Chen EX et al (2019) CCTG CO.26 trial: a phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC). J Clin Oncol 37(4_suppl):481–481CrossRef Chen EX et al (2019) CCTG CO.26 trial: a phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC). J Clin Oncol 37(4_suppl):481–481CrossRef
48.
Zurück zum Zitat Mayer RJ et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909–1919PubMedCrossRef Mayer RJ et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909–1919PubMedCrossRef
49.
Zurück zum Zitat Grothey A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303–312PubMedCrossRef Grothey A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303–312PubMedCrossRef
51.
Zurück zum Zitat Cremolini C et al (2019) Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol 5(3):343–350PubMedCrossRef Cremolini C et al (2019) Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol 5(3):343–350PubMedCrossRef
52.
53.
54.
Zurück zum Zitat Doebele RC et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 21(2):271–282PubMedCrossRef Doebele RC et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 21(2):271–282PubMedCrossRef
55.
Zurück zum Zitat Sartore-Bianchi A et al (2016) Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 17(6):738–746PubMedCrossRef Sartore-Bianchi A et al (2016) Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 17(6):738–746PubMedCrossRef
Metadaten
Titel
Systemische Therapie des metastasierten Kolonkarzinoms
Strategien in der Kombinations- und Sequenztherapie
verfasst von
Dr. med. Annika Kurreck
Dominik P. Modest
Jobst von Einem
Sebastian Stintzing
Publikationsdatum
11.12.2020
Verlag
Springer Medizin
Erschienen in
Die Onkologie / Ausgabe 3/2021
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-020-00875-7

Weitere Artikel der Ausgabe 3/2021

Die Onkologie 3/2021 Zur Ausgabe

Passend zum Thema

ANZEIGE

Synergien nutzen gegen Tumore

Lungen- und Magentumore können dank Immuntherapien deutlich besser behandelt werden. Dennoch kommt es trotzdem weiterhin häufig zum Krankheitsprogress. Welche Therapieoptionen sich in der Zweitlinie am besten eignen, haben wir für Sie zusammengefasst.

ANZEIGE

Darmkrebsreihenuntersuchungen zeigen EU-weit Erfolge

In Europa haben viele Länder dem Darmkrebs mit Hilfe von Früherkennungsprogrammen den Kampf angesagt. Es gibt einen deutlichen Zusammenhang zwischen Inzidenz und Mortalität von Darmkrebs und der Zeitspanne seit Einführung von Reihenuntersuchungen.

ANZEIGE

GI-Tumore und die Rolle von Angiogenesehemmern

Content Hub

Entdecken Sie mit praxisrelevanten Patientenfällen, kompakten Studieninhalten, informativen Experteninterviews und weiteren spannenden Inhalten, wie Sie den vielseitigen Herausforderungen bei GI-Tumoren begegnen können. Hier erfahren Sie mehr! PP-RB-DE-2009